Citi initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $16 price target Wave is a clinical-staged biotech company developing a pipeline of RNA medicines for rare and common diseases, the analyst tells investors in a research note. The firm sees several near-term data catalysts for Wave with potential for upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Promising RNA Therapies and Strong Financial Position Support Buy Rating
- Wave Life Sciences: Promising RNA Editing Developments and Positive Stock Outlook
- Wave Life Sciences’ WVE-007: Undervalued Potential in Obesity Treatment with Promising Preclinical Results
- Wave Life Sciences assumed with an Outperform at Raymond James
- Wave Life Sciences announces appointment of Wright as CMO